JMI LABS IS NOW PART OF LEARN MORE

Interim use of Vancomycin Susceptibility Testing Results to Predict Activity of Oritavancin, a New Long Acting Lipoglycopeptide, Lead author: Jones RN, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

View publication